Patents by Inventor Oretta Finco
Oretta Finco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10716842Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CTI 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: GrantFiled: January 29, 2019Date of Patent: July 21, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Guido Grandi, Renata Maria Grifantini, Oretta Finco
-
Publication number: 20190282685Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CTI 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: January 29, 2019Publication date: September 19, 2019Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Guido GRANDI, Renata Maria GRIFANTINI, Oretta FINCO
-
Patent number: 9987345Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.Type: GrantFiled: July 21, 2015Date of Patent: June 5, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Renata Maria Grifantini, Oretta Finco, Erika Bartolini, Guido Grandi
-
Publication number: 20180092970Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: May 9, 2017Publication date: April 5, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Guido GRANDI, Renata Maria GRIFANTINI, Oretta FINCO
-
Publication number: 20180036402Abstract: A method of immunization against Group B Streptococcus infection, using an immunogenic composition conjugates of GBS capsular saccharide conjugated to carrier proteins.Type: ApplicationFiled: September 15, 2017Publication date: February 8, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERTI, Mario CONTORNI, Paolo COSTANTINO, Oretta FINCO, Guido GRANDI, Domenico MAIONE, John TELFORD
-
Patent number: 9675683Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: GrantFiled: August 20, 2015Date of Patent: June 13, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Guido Grandi, Renata Maria Grifantini, Oretta Finco
-
Publication number: 20160158337Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: August 20, 2015Publication date: June 9, 2016Inventors: Guido GRANDI, Renata Maria Grifantini, Oretta Finco
-
Publication number: 20160067327Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: July 21, 2015Publication date: March 10, 2016Inventors: Renata Maria Grifantini, Oretta Finco, Erika Bartolini, Guido Grandi
-
Publication number: 20150283232Abstract: The invention provides an immunogenic composition comprising: (a) a conjugate that is a capsular saccharide from GBS serotype I1 conjugated to a carrier protein; (b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; and (c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunizing a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunized with a diphtheria toxoid or derivative thereof.Type: ApplicationFiled: March 19, 2015Publication date: October 8, 2015Inventors: Francesco BERTI, Mario CONTORNI, Paolo COSTANTINO, Oretta FINCO, Guido Grandi, Domenico MAIONE, John Telford
-
Patent number: 9151756Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: GrantFiled: September 24, 2013Date of Patent: October 6, 2015Assignee: Glaxosmithkline Biologicals SAInventors: Guido Grandi, Renata Maria Grifantini, Oretta Finco
-
Patent number: 9125864Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.Type: GrantFiled: June 10, 2011Date of Patent: September 8, 2015Assignee: Novartis AGInventors: Renata Maria Grifantini, Erika Bartolini, Oretta Finco, Guido Grandi
-
Publication number: 20140093510Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT1 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: September 24, 2013Publication date: April 3, 2014Applicant: Novartis AGInventors: Guido GRANDI, Renata Maria Grifantini, Oretta Finco
-
Patent number: 8568732Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: GrantFiled: March 8, 2010Date of Patent: October 29, 2013Assignee: Novartis AGInventors: Guido Grandi, Oretta Finco, Renata Maria Grifantini
-
Publication number: 20130273091Abstract: The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype 1a conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype 1b conjugated to a carrier protein; and c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunising a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunised with a diphtheria toxoid or derivative thereof.Type: ApplicationFiled: September 16, 2011Publication date: October 17, 2013Inventors: Francesco Berti, Mario Contorni, Paolo Costantino, Oretta Finco, Guido Grandi, Domenico Maione, John Telford
-
Publication number: 20130195907Abstract: The invention is in the field of outer membrane vesicles (OMV) and their uses. More particularly the present invention provides OMV obtained from a bacterium being an ompA mutant and/or a mutant in one or more components of the TolPal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of Chlamydia trachomatis CT823, CT681, CT372, CT443, CT043, CT733, CT279, CT601 and CT153 for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: June 10, 2011Publication date: August 1, 2013Applicant: Norvartis AGInventors: Renata Maria Grifantini, Erika Bartolini, Oretta Finco, Guido Grandi
-
Publication number: 20120093851Abstract: The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT1 53, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.Type: ApplicationFiled: March 8, 2010Publication date: April 19, 2012Inventors: Guido Grandi, Oretta Finco, Renata Maria Grifantini
-
Publication number: 20110070266Abstract: The invention relates to immunogenic compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises Chlamydia trachomatis antigens for eliciting a Chlamydia trachomatis specific TH1 immune response and another component of which comprises antigens for eliciting a Chlamydia trachomatis specific TH2 immune response. The invention further relates to an immunogenic composition comprising a Chlamydia trachomatis Type III secretion system (TTSS) regulatory protein and a Chlamydia trachomatis Type III secretion system (TTSS) secreted protein or a fragment thereof. The invention further relates to the use of combinations of adjuvants for use with antigens associated with a sexually transmissible disease, such as Chlamydia trachomatis antigens. Preferred adjuvant combinations include mineral salts, such as aluminium salts and oligonucleotides comprising a CpG motif.Type: ApplicationFiled: October 1, 2010Publication date: March 24, 2011Inventors: Guido Grandi, Giulio Ratti, Alessandra Bonci, Oretta Finco
-
Publication number: 20100255002Abstract: The invention relates to compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. Specific combinations may be selected from a first antigen group of PepA, LcrE, ArtJ, DnaK, and CT398, and a second antigen group of PepA, LcrE, ArtJ, DnaK, CT398, OmpH-like, L7/L12, OmcA, AtoS, CT547, Eno, HtrA and MurG. The invention further relates to the use of combinations of adjuvants for use with antigens associated with a sexually transmissible disease, such as Chlamydia trachomatis antigens. Preferred adjuvant combinations include mineral salts, such as aluminium salts and oligonucleotides comprising a CpG motif.Type: ApplicationFiled: June 25, 2004Publication date: October 7, 2010Applicant: CHIRON CORPORATIONInventors: Guido Grandi, Oretta Finco, Giulio Ratti, Alessandro Bonci
-
Publication number: 20060034871Abstract: The invention relates to immunogenic compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises Chlamydia trachomatis antigens for eliciting a Chlamydia trachomatis specific TH1 immune response and another component of which comprises antigens for eliciting a Chlamydia trachomatis specific TH2 immune response. The invention further relates to an immunogenic composition comprising a Chlamydia trachomatis Type III secretion system (TTSS) regulatory protein and a Chlamydia trachomatis Type III secretion system (TTSS) secreted protein or a fragment thereof. The invention further relates to the use of combinations of adjuvants for use with antigens associated with a sexually transmissible disease, such as Chlamydia trachomatis antigens. Preferred adjuvant combinations include mineral salts, such as aluminium salts and oligonucleotides comprising a CpG motif.Type: ApplicationFiled: December 22, 2004Publication date: February 16, 2006Applicant: Chiron CorporationInventors: Guido Grandi, Guilio Ratti, Alessandra Bonci, Oretta Finco